Drugs / CXA-10
CXA-10
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02547402 | Dec 2015 → Jan 2016 | acute kidney injury | Complexa, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02248051 | Sep 2014 → Aug 2015 | acute kidney injury | Complexa, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02127190 | Apr → Sep 2014 | acute kidney injury | Complexa, Inc. | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT03762395 | Feb 2023 → Nov 2029 expected | asthma, obesity disorder | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 2 | NCT04125745 | Oct 2019 → Dec 2020 | pulmonary arterial hypertension | Gladwin, Mark, MD | Terminated | No outcome recorded |
| Phase 2 | NCT04053543 | Aug 2019 → Aug 2020 | pulmonary arterial hypertension | Complexa, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT03422510 | Apr 2018 → Jul 2020 | primary focal segmental glomerulosclerosis | Complexa, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03680976 | ? → Apr 2021 | asthma | Sally E. Wenzel MD | Withdrawn | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02460146 Comparator | Apr → Sep 2015 | acute kidney injury | Complexa, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02313064 Comparator | Jan → May 2015 | chronic kidney disease | Complexa, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03449524 Comparator | Aug 2018 → Aug 2020 | pulmonary arterial hypertension | Complexa, Inc. | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CXA-10 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04053543 ↗ |
| Known as | 10-nitro-9(E)-octadec-9-enoic acid | “CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)” NCT03449524 ↗3“CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)” NCT03422510 ↗ “CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid” NCT02547402 ↗ “CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid” NCT02460146 ↗ |
| Known as | 10-nitro-oleic acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL561371 ↗ |
| Known as | E-10-no2-18:1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL561371 ↗ |
| Known as | Oa-no2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL561371 ↗ |
| Action | Inhibit | “inhibit systemic and pulmonary inflammation” NCT03762395 ↗ |
| Modality | Small molecule | “how a synthetic nitro-fatty acid (CXA-10, 10-nitro-octadec-9-enoic acid) suppresses the systemic and airway inflammation” NCT03762395 ↗ |
| Route | Intravenous | “CXA-10 Injectable Emulsion will be administered intravenously.” NCT02127190 ↗ |